Anti-proteolytic regulation of KRAS by USP9X/NDRG3 in KRAS-driven cancer development
Abstract Cancers with activating mutations of KRAS show a high prevalence but remain intractable, requiring innovative strategies to overcome the poor targetability of KRAS. Here, we report that KRAS expression is post-translationally up-regulated through deubiquitination when the scaffolding functi...
Saved in:
Main Authors: | Han Koo, Kyung Chan Park, Hyun Ahm Sohn, Minho Kang, Dong Joon Kim, Zee-Yong Park, Sehoon Park, Sang Hyun Min, Seong-Hwan Park, Yeon-Mi You, Yohan Han, Bo-Kyung Kim, Chul-Ho Lee, Yeon-Soo Kim, Sang J. Chung, Young Il Yeom, Dong Chul Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-024-54476-8 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Multiomic quantification of the KRAS mutation dosage improves the preoperative prediction of survival and recurrence in patients with pancreatic ductal adenocarcinoma
by: Won-Gun Yun, et al.
Published: (2025-01-01) -
A short history of »Kras«
by: Andrej Kranjc
Published: (2018-12-01) -
Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
by: Satoru Miyazaki, et al.
Published: (2025-02-01) -
Role of silent mutations in KRAS-mutant tumors
by: Jun Lu, et al.
Published: (2025-02-01) -
p53 dosage can impede KrasG12D- and KrasQ61R-mediated tumorigenesis.
by: Özgün Le Roux, et al.
Published: (2024-01-01)